Key result
Acarbose therapy significantly decreased the risk of recurrent MACE compared to no acarbose (26.67% vs 46.88%; P<0.05) in patients with ACS and newly diagnosed impaired glucose tolerance.
Why the study?
Does acarbose reduce the incidence of major adverse cardiovascular events in patients with acute coronary syndromes and newly diagnosed impaired glucose tolerance?
RCT (n=135)
Randomly assigned
Does acarbose reduce the incidence of major adverse cardiovascular events in patients with acute coronary syndromes and newly diagnosed impaired glucose tolerance?
Absolute Event Rate: 26.67% vs 46.88%
p-value: p=<0.05
Acarbose therapy may improve long-term cardiovascular outcomes and slow atherosclerosis progression in ACS patients with newly diagnosed impaired glucose tolerance.
Supports acarbose for MACE reduction in ACS with new IGT; extends RCT evidence on postprandial glucose control post-ACS.
OBJECTIVE: To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT). METHODOLOGY: 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day, n = 67) or control group (no acarbose, n = 68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed. RESULTS: During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%, P < 0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm, P < 0.05). CONCLUSIONS: Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2015) conducted an RCT in Acute coronary syndromes with newly diagnosed impaired glucose tolerance (n=135). Acarbose vs. No acarbose was evaluated on Incidence of major adverse cardiovascular event (MACE) (p=<0.05). Acarbose therapy significantly decreased the risk of recurrent MACE compared to no acarbose (26.67% vs 46.88%; P<0.05) in patients with ACS and newly diagnosed impaired glucose tolerance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: